AFP and hepatocellular carcinoma: Starting with the adoption of Milan criteria in 1996 [6], several selection criteria, including tumor radiologic and pathologic characteristics (number, diameter), circulating biomarkers (serum AFP) and dynamic response evaluation of neoadjuvant therapies (e.g., TACE) have been developed to improve the prediction of recurrence after LT in HCC patients [31].